Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer

J Thorac Oncol. 2013 May;8(5):e41-2. doi: 10.1097/JTO.0b013e31828bb1b3.
No abstract available

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Carcinoma, Non-Small-Cell Lung / genetics*
  • Drug Resistance, Neoplasm / genetics*
  • Female
  • Humans
  • Imidazoles / therapeutic use
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / genetics*
  • MAP Kinase Signaling System / genetics*
  • Middle Aged
  • Mutation
  • Oximes / therapeutic use
  • Proto-Oncogene Proteins / genetics*
  • Proto-Oncogene Proteins B-raf / genetics*
  • Proto-Oncogene Proteins p21(ras)
  • ras Proteins / genetics*

Substances

  • Antineoplastic Agents
  • Imidazoles
  • KRAS protein, human
  • Oximes
  • Proto-Oncogene Proteins
  • Proto-Oncogene Proteins B-raf
  • Proto-Oncogene Proteins p21(ras)
  • ras Proteins
  • dabrafenib